0000899243-21-002759.txt : 20210121 0000899243-21-002759.hdr.sgml : 20210121 20210121192428 ACCESSION NUMBER: 0000899243-21-002759 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210119 FILED AS OF DATE: 20210121 DATE AS OF CHANGE: 20210121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Miller Edward CENTRAL INDEX KEY: 0001619252 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39409 FILM NUMBER: 21543314 MAIL ADDRESS: STREET 1: C/O ALEXION PHARMACEUTICALS, INC STREET 2: 352 KNOTTER DRIVE CITY: CHESHIRE STATE: CT ZIP: 06410 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Allovir, Inc. CENTRAL INDEX KEY: 0001754068 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 831971007 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 139 MAIN STREET, SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 433-2605 MAIL ADDRESS: STREET 1: 139 MAIN STREET, SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: ViraCyte, Inc. DATE OF NAME CHANGE: 20180924 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-01-19 0 0001754068 Allovir, Inc. ALVR 0001619252 Miller Edward C/O ALLOVIR, INC. 139 MAIN STREET, SUITE 500 CAMBRIDGE MA 02142 0 1 0 0 General Counsel Common Stock 2020-12-01 5 G 0 E 41514 0.00 D 166051 D Common Stock 2020-12-01 5 G 0 E 41514 0.00 A 198811 I See Footnote Common Stock 2021-01-19 4 A 0 28000 0.00 A 194051 D Stock Option (Right to Buy) 42.15 2021-01-19 4 A 0 52000 0.00 A 2031-01-19 Common Stock 52000 52000 D On December 1, 2020, the Reporting Person transferred 41,514 shares to The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter. 25% of this option shall vest and become exercisable on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter. /s/ Brett Hagen, as Attorney-in-Fact 2021-01-21